Skip to content
Dose Brief
Menu

Provider review

Trellis Vitality review: $150 semaglutide

Trellis Vitality’s dated review compares GLP-1 plan lengths, starting prices for other programs, named care partners and state-eligibility limits.

By The Dose Brief Desk, News Editor

Updated · Editorial standards

In this brief

Provider prices and program details below reflect the September 1, 2026 source review. The October editorial correction does not refresh those quotes or independently verify current clinician or pharmacy credentials.

Trellis Vitality publishes a GLP-1 price table with separate one-, three- and six-month terms. The other four injectable programs in the reviewed catalog had starting prices without comparable dose-by-dose tables. That difference makes the GLP-1 offer easier to evaluate, while the other programs require a more specific quote. See the Trellis Vitality provider profile for the summary and rating.

The GLP-1 table is the good one

Semaglutide is $150 a month on a one-month plan, $140 a month on three, and $133 a month on six. Tirzepatide is $199, $189 and $179 across the same three terms. The table is rendered as plain HTML on the program page, behind no quiz and no email gate, labeled "per-month price; longer plans cost less per month", with a second line stating that all dosages are available at the same price.1

The one-month column is explicitly the month-to-month rung, which is the detail that makes the rest of the table safe to quote. A prepay figure printed as a monthly rate is the error that puts unbuyable numbers at the top of cheapest-first rankings; this table cannot produce it, because the term is named above every column. At $150 for semaglutide, Trellis undercuts most of what sits on our semaglutide wire, and its $199 tirzepatide is a fair rate against the going rate for that molecule.

And then the rest of the shelf

NAD+ is Trellis's flagship. Its page says treatment plans start at $129 a month. That is the entire pricing disclosure. Glutathione starts at $93, lipo-MIC with B12 at $130, tesamorelin at $299 — four programs, four single figures, no rung table anywhere.1 The reviewed public pages and NAD+ enrollment information did not give a dose-specific price.

So we file those four as "from $129, full ladder not published" and we will not print any of them as a monthly rate. Here is why that matters rather than being pedantic: on the one program where Trellis does publish a ladder, the six-month rung sits about 12 per cent below the one-month rung. If the same structure applies to NAD+, then $129 is the six-month rung and the month-to-month price is higher. That is an inference, not an observation, and an inference is not a price.

The claim its own blog makes

Trellis's blog post on NAD+ injection cost, updated in July 2026, states twice that Trellis publishes its complete pricing on the program page. It does not. The program page publishes one "starting at" figure, which is the specific thing that post criticizes competitors for doing. We are not calling that dishonest — marketing copy drifts from product reality constantly, and this reads like a page written against an intention rather than against the site. But a provider that advertises its pricing transparency is inviting exactly this check, and it fails it on four of its five programs.

The same page furniture carries a star rating, a current-patient count and an average annual savings figure, none of which is sourced anywhere on the site. We do not repeat unsourced marketing statistics, so we have not printed them.

Who is behind it

The medicine is practiced by Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449 — active in the federal NPPES registry, family medicine.2 The pharmacy is VialsRX, a state-licensed compounding pharmacy in Houston, and Trellis names it in its own machine-readable site file rather than making you hunt for it. Naming a pharmacy at all puts Trellis in the minority of the providers we read this month, and it is the check our five-minute provider checklist puts second. Intake and billing run on Bask Health. The site claims board-certified physicians in all 50 states — but on a re-read of 1 September 2026 the GLP-1 program's own FAQ says the opposite in the same breath: the program "is not offered in every state", and it names Connecticut, Ohio and South Carolina as places it is currently suppressed. The banner is sitewide; the exclusion is on the page you would actually buy from.

What is not published is the corporate entity. The terms page runs to about three kilobytes of text and never names an LLC or a corporation, so there is no filing name to look up. For a provider this forthcoming about its pharmacy, that is an odd omission.

The overlap with The Edit

The reviewed disclosures name Arora Health & Aesthetics and Sean Arora for both Trellis and The Edit. They are separate brands with different published pharmacies, catalogs and prices, but share a named clinical group. That relationship does not establish that the same clinician will see every patient. Ask who would handle your care if comparing them for a second opinion.

Fees and the exit

Trellis advertises no membership and no consult cost, and a free assessment to start. We could not corroborate any of that in a terms document, because the terms document barely exists. There is no evidence of a fee charged regardless of outcome, and no evidence of the opposite either — the disclosure is thin rather than adverse. On the programs where the ladder is published, the shortest term is one month, so the exit is a month away rather than a contract away, which is more than Rehydra+ can say.

The regulatory screen

The August 2026 FDA warning-letter search did not identify company-name matches for the brand, medical group or pharmacy.3 This limited, dated result is not approval or a complete regulatory history. A published LegitScript seal identifier alone did not establish certification ownership in this review.

Where it lands

Trellis’s recorded GLP-1 table distinguishes plan lengths and names care partners. Prices for NAD+, glutathione, lipo-MIC and tesamorelin remained starting figures rather than complete quotes. Confirm current terms and state eligibility before enrolling; the research library provides context on the treatments themselves.

Frequently asked questions

How much does Trellis Vitality cost per month?

Semaglutide is $150 a month on a one-month plan, $140 on a three-month plan and $133 on six months. Tirzepatide is $199, $189 and $179 across the same terms. All doses cost the same within a program.

What does NAD+ cost at Trellis?

It says treatment plans start at $129 a month and publishes nothing else — no rung table, no term breakdown. Because its GLP-1 six-month rung sits about 12 per cent below its one-month rung, $129 may well be a prepay figure rather than a monthly rate. Treat it as a floor.

Does Trellis Vitality name its pharmacy?

Yes — VialsRX, a state-licensed compounding pharmacy in Houston, Texas, named in the site's own machine-readable file. Its medical director, Dr. Sean Arora, publishes an NPI that is active in the federal registry.

Is Trellis Vitality related to The Edit?

They are separate brands with different published pharmacies, catalogs and prices, but their disclosures name the same medical group, Arora Health & Aesthetics, and medical director Sean Arora. That does not establish the clinician assigned to an individual patient.

References

  1. Trellis Vitality (2026). GLP-1, NAD+, glutathione, lipo-MIC and tesamorelin program pages. trellisvitality.com. https://trellisvitality.com/
  2. Centers for Medicare & Medicaid Services (2026). NPPES NPI Registry. npiregistry.cms.hhs.gov. https://npiregistry.cms.hhs.gov/
  3. U.S. Food and Drug Administration (2026). Warning Letters. FDA. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.